Aptevo Therapeutics (APVO) Fundamental Analysis: Revenue, Earnings & Valuation

3.28 / 10

Netural

Fundamental rating is Neutral with a 3.3/10 quality score. Gross profit margin stands at 36% and fixed‑asset turnover is high, while inventory turnover is strong. However, current‑asset turnover is low and income‑tax ratio is elevated, making the fundamentals selective.

Analysis Checks(4/6)

Inventory turnover ratio

Value53.13

Score2/3

Weight26.32%

1M Return-0.56%

Gross profit margin (%)

Value36.07

Score2/3

Weight-91.96%

1M Return1.67%

Income tax / Total profit (%)

Value17.97

Score1/3

Weight-10.02%

1M Return0.21%

Current assets turnover ratio

Value2.27

Score1/3

Weight8.91%

1M Return-0.17%

Fixed assets turnover ratio

Value1812.88

Score2/3

Weight-0.49%

1M Return0.01%

Cost of sales ratio (%)

Value71.86

Score2/3

Weight167.24%

1M Return-3.62%

Is APVO undervalued or overvalued?

APVO scores 3.28/10 on fundamentals and holds a Fair valuation at present. Backed by its -248.81% ROE, 0.00% net margin, -0.18 P/E ratio, 0.29 P/B ratio, and 99.72% earnings growth, these metrics solidify its Netural investment rating.